Acquisition by Jeffrey Wade of 147340 shares of Lexicon Pharmaceuticals subject to Rule 16b-3

LXRX Stock  USD 1.56  0.02  1.27%   
Slightly above 64% of all Lexicon Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Lexicon Pharmaceuticals suggests that some traders are interested. Lexicon Pharmaceuticals' investor sentiment overview provides quick insight into current market opportunities from investing in Lexicon Pharmaceuticals. The current market sentiment, together with Lexicon Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Lexicon Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Lexicon Pharmaceuticals stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Lexicon daily returns and investor perception about the current price of Lexicon Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
  
Filed transaction by Lexicon Pharmaceuticals I officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Lexicon insider trading alert for grant of restricted stock units by Jeffrey Wade, President and CFO, on 13th of February 2023. This event was filed by Lexicon Pharmaceuticals I with SEC on 2023-02-13. Statement of changes in beneficial ownership - SEC Form 4. Jeffrey Wade currently serves as cfo, executive vice president - corporate development of Lexicon Pharmaceuticals

Cash Flow Correlation

Lexicon Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Lexicon Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Lexicon Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Lexicon Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Lexicon Pharmaceuticals Fundamental Analysis

We analyze Lexicon Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexicon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexicon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Earnings Per Share

Earnings Per Share Comparative Analysis

Lexicon Pharmaceuticals is currently under evaluation in earnings per share category among related companies. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Lexicon Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lexicon Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Lexicon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lexicon Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Lexicon Pharmaceuticals Related Equities

IBRXImmunitybio   22.31   
0%
100.0%
OCEAOcean Biomedical   17.16   
0%
76.0%
DAWNDay One   10.46   
0%
46.0%
MCRBSeres Therapeutics   9.64   
0%
43.0%
EFTREffector Therapeutics   9.52   
0%
42.0%
ELEVElevation Oncology   6.35   
0%
28.0%
HEPAHepion Pharmaceuticals   6.20   
0%
27.0%
HOOKHookipa Pharma   5.62   
0%
25.0%
ENVBEnveric Biosciences   5.56   
0%
24.0%
BLRXBioLineRx   4.92   
0%
22.0%
TERNTerns Pharmaceuticals   3.87   
0%
17.0%
MREOMereo BioPharma   0.73   
0%
3.0%
ARDXArdelyx   0.62   
0%
2.0%
AVROAVROBIO   1.65   
7.0%
0%
GRTXGalera Therapeutics   5.26   
23.0%
0%
XFORX4 Pharmaceuticals   6.84   
30.0%
0%
When determining whether Lexicon Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lexicon Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lexicon Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lexicon Pharmaceuticals Stock:
Check out Lexicon Pharmaceuticals Hype Analysis, Lexicon Pharmaceuticals Correlation and Lexicon Pharmaceuticals Performance.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Lexicon Stock analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Bonds Directory
Find actively traded corporate debentures issued by US companies
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Is Lexicon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceuticals. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.63)
Earnings Share
(0.80)
Revenue Per Share
0.005
Quarterly Revenue Growth
24.071
Return On Assets
(0.51)
The market value of Lexicon Pharmaceuticals is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lexicon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexicon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexicon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.